Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Harry P. Erba, Arnaud Pigneux, Heinz August Horst, Christian Recher, Virginia M. Klimek, Jorge Cortes, Gail J. Roboz, Olatoyosi Odenike, Xavier Thomas, Violaine Havelange, Johan MaertensHans Günter Derigs, Michael Heuser, Lloyd Damon, Bayard L. Powell, Gianluca Gaidano, Angelo Michele Carella, Andrew Wei, Donna Hogge, Adam R. Craig, Judith A. Fox, Renee Ward, Jennifer A. Smith, Gary Acton, Cyrus Mehta, Robert K. Stuart, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Fingerprint Dive into the research topics of 'Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences